Nappo, Floriana
Fornaro, Lorenzo
Pompella, Luca
Catanese, Silvia
Lavacchi, Daniele
Spallanzani, Andrea
Cappetta, Alessandro
Puzzoni, Marco
Murgioni, Sabina
Barsotti, Giulia
Tirino, Giuseppe
Pellino, Antonio
Vivaldi, Caterina
Strippoli, Antonia
Aprile, Giuseppe
Di Donato, Samantha
Mazza, Elena
Prisciandaro, Michele
Antonuzzo, Lorenzo
Zagonel, Vittorina
Cascinu, Stefano
De Vita, Ferdinando
Lonardi, Sara
Article History
Received: 10 December 2022
Accepted: 4 February 2023
First Online: 16 February 2023
Declarations
:
: Nothing directly related to this work. Out of this work, Lorenzo Fornaro received Honoraria from Lilly and server and had roles as consultant or advisor for MSD, Servier, Lilly, he received research funding from Merck Sharp & Dohme Gilead Sciences. Andrea Spallanzani had roles as a consultant or advisor for Lilly, Pierre-Fabre. Caterina Vivaldi had roles as consultant or advisor for Roche; she is part of the speackers’bureau of Bayer, TERUMO. Stefano Cascinu had roles as consultant or advisor for BMS, Lilly, MSD Oncology, Servier, he is part of speakers’bureau of Lilly, Servier. Vittorina Zagonel received had roles as consultant or advisor for Astellas Pharma, Bayer, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Servier Ferdinando De Vita had roles as consultant or advisor for BMSi, Lilly, MSD, Servier. Sara Lonardi had roles as consultant or advisor for Amgen, Astra Zeneca, Bristol-Myers Squibb, Daiichi-Sankyo, Incyte, Lilly, Merck Serono, MSD, Servier, she received research funding from Amgen, Astellas, Astra-Zeneca, Bayer, BMS Daichii Sankyo, Hutchinson, Incyte, Merck Serono, Mirati, MSD, Pfizer, Roche and she is part of speakers’ bureau of Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Merck Serono, Pierre Fabre, Roche, Servier. All the other authors declare no conflict of interest regarding the publication of this article.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation of the Veneto Institute of Oncology (IOV)–IRCCS and with the Helsinki Declaration of 1964 and later versions.